The COVID-19 pandemic threatens to reverse recent progress in reducing the global burden of tuberculosis. The global number of deaths for tuberculosis could increase by around 200.000–400.000 in 2020 alone, as result of essential tuberculosis services disruptions due to the reallocation of human, financial and other resources from tuberculosis to the COVID-19 response, as reported by WHO: https://bit.ly/35KyzD
Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including
Pregnant women, babies and children under 5 years of age are the most vulnerable to malaria. In 2018, around 11 million pregnant women and 24 million children got malaria. Furthermore,
An international research team has begun patient enrollment in a clinical trial testing multiple investigational Ebola therapies in the Democratic Republic of the Congo (DRC). The randomized, controlled trial is